Graph Neural Network Can Detect Epileptogenic Focal Cortical Dysplasia
By Elana Gotkine HealthDay Reporter
WEDNESDAY, March 19, 2025 -- A graph neural network using data from the Multicenter Epilepsy Lesion Detection (MELD) Project (MELD Graph) can detect epileptogenic focal cortical dysplasia (FCD) on magnetic resonance imaging (MRI) scans, with improved positive predictive value (PPV) compared with an existing algorithm, according to a study published online Feb. 24 in JAMA Neurology.
Mathilde Ripart, Ph.D., from the UCL Great Ormond Street Institute of Child Health in London, and colleagues examined the efficacy and interpretability of graph neural networks in automatically detecting FCD lesions on MRI scans in a multicenter diagnostic study. Retrospective MRI data were obtained from 23 epilepsy centers worldwide between 2018 and 2022. Data from 20 centers were split into training and testing cohorts, and data from three centers were used for site-independent testing. MELD Graph was trained to identify FCD on surface-based features; performance was compared to that of an existing algorithm. Overall, 34 surface-based MRI features and manual lesion masks were obtained from 703 patients with FCD-related epilepsy and 482 controls.
The researchers found that the MELD Graph had a sensitivity of 81.6 and 63.7 percent in histopathologically confirmed patients who were seizure-free one year after surgery and in MRI-negative patients with FCD, respectively, in the test dataset. The PPV was 67 percent for 260 patients in the test dataset compared with 39 percent using an existing baseline algorithm. In the independent test cohort, the corresponding PPVs were 76 and 46 percent.
"With improved performance over existing methods, interpretable predictions, model confidence scores, and individual patient reports, MELD Graph can support the integration of lesion detection tools into the radiological workflow," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted March 2025
Read this next
Rebound Weight Gain Common After Discontinuing Antiobesity Medications
FRIDAY, July 25, 2025 -- Antiobesity medications (AOMs) yield weight loss during use, followed by weight regain after discontinuation of treatment, according to a review published...
Patients Face High Out-of-Pocket Costs After Incident Cancer Diagnosis
FRIDAY, July 25, 2025 -- Patients face high out-of-pocket costs (OOPCs) after an incident diagnosis of cancer, with costs increasing with stage of diagnosis, according to a study...
Exposure to PFAS Mixtures Linked to Increased Odds of Type 2 Diabetes
FRIDAY, July 25, 2025 -- In multiethnic populations, exposure to per- and polyfluoroalkyl substance (PFAS) mixtures may be associated with increased odds of type 2 diabetes (T2D)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.